This study looks at how well two drugs, tarlatamab and durvalumab, work together compared to durvalumab alone for treating a type of lung cancer called extensive-stage small-cell lung cancer (ES-SCLC). Participants should be adults who have already had some chemotherapy and are stable without disease progression. They must have a life expectancy of at least 12 weeks and meet other health criteria.
- Length and Visits: The study requires completing all visits and procedures as outlined.
- Compensation: Information on compensation is not provided, check with the study team.
- Risks: There may be risks from the study drugs or procedures, discuss these with the study doctor.
Some people cannot join the study, such as those with certain health conditions like brain problems or recent heart issues. Women who are pregnant, breastfeeding, or planning to become pregnant cannot join. Men should agree to certain conditions if their partner can become pregnant. This study will help find better ways to treat this lung cancer, but participants should discuss with their doctor to know if it's right for them.